Enurev Breezhaler


glycopyrronium bromide

This medicine is authorised for use in the European Union.


Enurev Breezhaler is a medicine that is used to relieve the symptoms of chronic obstructive pulmonary disease (COPD) in adults. COPD is a long-term disease in which the airways and air sacs inside the lungs become damaged or blocked, leading to difficulty breathing. Enurev Breezhaler is used for maintenance (regular) treatment.

Enurev Breezhaler contains the active substance glycopyrronium bromide.

This EPAR was last updated on 10/11/2021

Authorisation details

Product details
Enurev Breezhaler
Agency product number
Active substance
glycopyrronium bromide
International non-proprietary name (INN) or common name
glycopyrronium bromide
Therapeutic area (MeSH)
Pulmonary Disease, Chronic Obstructive
Anatomical therapeutic chemical (ATC) code
Publication details
Marketing-authorisation holder
Novartis Europharm Ltd
Date of issue of marketing authorisation valid throughout the European Union
Contact address
Novartis Europharm Limited
Elm Park
Merrion Road
Dublin 4

Product information

28/10/2021 Enurev Breezhaler - EMEA/H/C/002691 - WS2176

Product information documents contain:

You can find product information documents for centrally authorised human medicines on this website. For centrally authorised veterinary medicines authorised or updated from February 2022, see the Veterinary Medicines Information website.

Pharmacotherapeutic group

Drugs for obstructive airway diseases

Therapeutic indication

Enurev Breezhaler is indicated as a maintenance bronchodilator treatment to relieve symptoms in adult patients with chronic obstructive pulmonary disease (COPD).

Assessment history

How useful was this page?

Add your rating
1 rating